Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Tarceva

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Tarceva was produced by Roche and Astellas.

Boehringer takes third-generation NSCLC drug into pivotal trials

Boehringer takes third-generation NSCLC drug into pivotal trials Tarceva (erlotinib) and AstraZeneca's Iressa (gefitinib), as well as Boehringer's own second-generation drug Giotrif (afatinib).

Oncology directions

Oncology directions Most of the drugs in lung cancer score four, but Roche's lung cancer drug Tarceva (erlotinib) scored just one.

Iressa set for US market return after FDA approval

Iressa set for US market return after FDA approval other first-generation EGFR inhibitors such as Roche/OSI's Tarceva (erlotinib) as well as newer drugs such as Boehringer Ingelheim's Giotrif (afatinib).

Lilly closes on US approval of lung cancer drug necitumumab

Lilly closes on US approval of lung cancer drug necitumumab Other drugs targeting EGFR are already on the market for NSCLC, including orally-active therapies such as Roche's Tarceva (erlotinib), AstraZeneca's Iressa (gefitinib) and Boehringer Ingelheim's Giotrif (afatinib). ... Boehringer has just reported phase

Boehringer plans new filings for Giotrif in lung cancer

Boehringer plans new filings for Giotrif in lung cancer The German pharma company reports that Giotrif (afatinib) was more effective than Roche's Tarceva (erlotinib) in extending the lives of previously treated SCC patients in the study, which has just ... In addition to Tarceva it also competes with Iressa

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

R&D protocol amendments
Rethinking trials: the pros and cons of protocol amendments
Protocol amendments occur often and can be beneficial, but the steps involved can be complex...
Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...

Infographics